NCT03428646

Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)

A Prospective Observational Study of Patients Receiving DUPIXENT® for Atopic Dermatitis

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 858 (actual)
• Sponsor: Regeneron Pharmaceuticals · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

A long-term observational registry in patients with atopic dermatitis (AD) initiating treatment with DUPIXENT® (dupilumab)

Detailed description

This is a prospective observational study conducted to (1) characterize the patients who receive DUPIXENT® for AD in a real world setting with respect to their medical history, socio-demographic and disease characteristics, and prior and concomitant treatments of AD; (2) characterize real world use patterns of DUPIXENT® for AD (eg, most commonly used regimens by line of therapy, reason for initiation of new treatments, concomitant therapies, treatment durations and reasons for discontinuation and/or switching); (3) assess the long-term effectiveness of DUPIXENT® in AD patients in a real world setting; (4) assess comorbid atopic conditions, patterns of use and effects of treatment in comorbid atopic conditions in patients who receive DUPIXENT® for AD; and (5) collect safety data on study participants

Conditions

• Dermatitis, Atopic

Interventions

Type	Name	Description
DRUG	Dupilumab	Dupixent 1 dose at Baseline required for eligibility; otherwise, no therapeutic intervention required during the course of the study. In addition to (or substituting for) DUPIXENT®, participants may receive marketed drugs as deemed necessary by their physicians for the treatment of AD or comorbid conditions.

Timeline

• Start date: 2018-04-06
• Primary completion: 2027-03-30
• Completion: 2027-03-30
• First posted: 2018-02-09
• Last updated: 2025-12-29

Locations

99 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study